StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Accounts Receivable by Year

Accounts Receivable ($M)

Novartis Accounts Receivable: $8,937M in FY2025, up 20.4% from a year earlier. That is the highest of the 10 years on record here.

Latest, FY2025
8,937
Period ended Dec 31, 2025
Change on a year earlier
+20.4%
7,423 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below

Where the FY2025 figure comes from

Source: Novartis 20-F (0001114448-26-000004, filed 2026-02-04) ↗

Reported in Postgres DB + Form 6-K.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Novartis Accounts Receivable ($M), annual FY2016–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/db-bs-ar

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.